70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
March 2025 in “SKIN The Journal of Cutaneous Medicine”
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
15 citations
,
March 2024 in “Journal of Clinical Medicine” Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
5 citations
,
January 2021 in “Dermatology Online Journal” An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
October 2025 in “Clinical Chemistry” Juniperus communis extract enhances the effectiveness of oral cancer treatment when combined with chemotherapy.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
37 citations
,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
7 citations
,
January 2009 in “BMJ Case Reports” Gefitinib can cause slower, finer, brittle, and curly scalp hair.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
January 2018 in “Journal of the American Academy of Dermatology” Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.